Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Axel A. Fauser"'
Autor:
Michael Flasshove, Markus Pfirrmann, Susanne Saußele, Wolf-K. Hofmann, M. P. Kraus, Benjamin Hanfstein, Urs Hess, Rüdiger Hehlmann, R. Mahlberg, Martin C. Müller, Gabriela M. Baerlocher, Tim H. Brümmendorf, Manuel Barreto Miranda, Dominik Heim, Christoph Nerl, Dieter K. Hossfeld, B. Rendenbach, Alice Fabarius, Walter Verbeek, Hans-Jochem Kolb, K. Neben, Stefan W. Krause, Otto Prümmer, Joerg Hasford, Axel A. Fauser, Ulrike Proetel, C. Ploger, Andreas Hochhaus, Michael Lauseker
Publikováno v:
Leukemia
Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, Gabriela M.; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; ... (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia, 30(6), pp. 1255-1262. Nature Publishing Group 10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, Gabriela M.; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; ... (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia, 30(6), pp. 1255-1262. Nature Publishing Group 10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Published by Nature Publ. Group, Basingstoke
Published by Nature Publ. Group, Basingstoke
Autor:
Michael Pfreundschuh, Matthias Edinger, Martin Wilhelm, Christiane Falge, Jörg Th. Fischer, Bernd Hertenstein, Markus Pfirrmann, Donald Bunjes, J Novotny, Susanne Schnittger, Michael Schatz, Artur Wehmeier, Andreas Hochhaus, Herbert G. Sayer, Ingo G.H. Schmidt-Wolf, Christoph Nerl, Claudia Haferlach, Susanne Saußele, Matthias Fabian, Martin C. Müller, Arnold Ganser, Joerg Hasford, Dieter K. Hossfeld, Anthony D. Ho, Hans-Jochem Kolb, Peter Staib, Herrmann Heimpel, Hartmut Döhner, Axel A. Fauser, Andreas Reiter, Michael Schenk, Renate Arnold, Gabriela M. Baerlocher, Rainer Schwerdtfeger, Carlo Aul, Rüdiger Hehlmann, Rolf Kuse, Thomas Kindler, Axel R. Zander, Gerald Wulf, Norbert Schmitz, Otto Prümmer, Karsten Spiekermann, Maria-Elisabeth Goebeler, Ute Berger, Anne Rosselet, Nicolaus Kröger, Dietrich W. Beelen, Alois Gratwohl, Günter Schlimok, Jiří Mayer, Andrzej Hellmann, Herrad Baurmann, Matthias Bormann, Hans Walter Lindemann, Christof Scheid, E. Schäfer, Guntram Büsche
Publikováno v:
Gratwohl, A; Pfirrmann, M; Zander, A; Kröger, N; Beelen, D; Novotny, J; Nerl, C; Scheid, C; Spiekermann, K; Mayer, J; Sayer, H G; Falge, C; Bunjes, D; Döhner, H; Ganser, A; Schmidt-Wolf, I; Schwerdtfeger, R; Baurmann, H; Kuse, R; Schmitz, N; ... (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 30(3), pp. 562-569. Nature Publishing Group 10.1038/leu.2015.281
Leukemia, vol. 30, no. 3, pp. 562-569
Leukemia
Leukemia, vol. 30, no. 3, pp. 562-569
Leukemia
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343c3126b8797d956f29c42c090048c4
https://doi.org/10.1038/leu.2015.281
https://doi.org/10.1038/leu.2015.281
Publikováno v:
Bone Marrow Transplantation. 45:355-362
A haematopoietic SCT (HSCT) can cause severe side effects, which may have a profound impact on a patient's life both physically and psychologically. Some studies have shown that physical activity has positive effects for inpatients after an HSCT. The
Autor:
Reza Tabrizzi, Vanderson Rocha, Mohamad Mohty, Didier Blaise, Arnon Nagler, Myriam Labopin, Johan Maertens, Ignazio Majolino, Niklas Theorin, Alessandro Rambaldi, Shimon Slavin, Axel A. Fauser
Publikováno v:
Haematologica. 93:303-306
This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leuke
Autor:
Lothar Kanz, Olga Marinets, Eckhard Thiel, Ulrich Keilholz, Lutz Uharek, Werner Hopfenmüller, Mathias Freund, H. Einsele, D. W. Beelen, Rudolf Trenschel, Jochen Casper, W. U. Knauf, Martin Schmidt-Hieber, Liisa Volin, Axel A. Fauser, Reinhard Andreesen, T Fietz, Gernot Stuhler, I. W. Blau, Tapani Ruutu
Publikováno v:
Bone Marrow Transplantation. 39:389-396
In recent years, reduced-intensity conditioning (RIC) regimens before allogeneic stem cell transplantation (SCT) are increasingly used in patients not eligible for conventional conditioning. We did a retrospective, multicenter analysis to assess the
Autor:
Axel A. Fauser, Dietrich W. Beelen, Oliver Basu, Nadezda Basara, Olle Ringdén, Mats Remberger
Publikováno v:
Blood. 105:548-551
The long-term follow-up of a study including 214 patients receiving either peripheral blood stem cells (PBSCs) or bone marrow (BM) from an HLA-A, -B, and -DR–compatible unrelated donor is presented. Median follow-up was 4.4 (2.3-7.3) and 5.0 (0.7-8
Autor:
D. W. Beelen, Axel A. Fauser, Nadezda Basara, R A Hilger, Mathias Freund, Joachim Hahn, M E Scheulen, Rudolf Trenschel, Jochen Casper, Joachim Baumgart, Bernd Hertenstein, Ernst Holler, Heidrun A. Mylius, Uwe Pichlmeier
Publikováno v:
Bone Marrow Transplantation. 35:233-241
Treosulphan has recently demonstrated antileukaemic activity and potent haematopoietic stem cell toxicity. Dose-escalated treosulphan (3 x 12 or 3 x 14 g/m2) combined with cyclophosphamide (Cy) was chosen for a new preparative regimen before allogene
Autor:
José A. Pérez-Simón, Han Myint, Axel R. Zander, Axel A. Fauser, Nicolaus Kröger, Rainer Schwerdtfeger, Hans G. Klingemann, Peter Liebisch, Hermann Einsele, Tatjana Zabelina, Avichai Shimoni, Georgia Schilling, Hannes Wandt, Judith Dierlamm, Arnon Nagler, Michael G. Kiehl, Axel Hinke, Herbert G. Sayer, Jesús F. San Miguel
Publikováno v:
ResearcherID
We investigated in a retrospective multicenter study the impact of chromosome arm 13q deletion (13q-) as detected by fluorescence in situ hybridization (FISH) on outcome after dose-reduced allografting in patients with multiple myeloma. In 68 of 140
Autor:
Boris Fehse, Rainer Loew, Nathalie Selevsek, Axel A. Fauser, Klaus Kuehlcke, Christopher Baum, Dorothee von Laer
Publikováno v:
Molecular Therapy. 9:738-746
Retroviral producer cells are generated by the introduction of a viral genome into "helper" cell lines containing all the necessary components for viral packaging and the release of infectious particles. The selection of high-titer vector producer ce
Autor:
Manfred Hensel, Thomas K. Held, Jörg Beyer, Christian Scheffold, A. D. Ho, Wolfgang Siegert, Axel A. Fauser, Johannes Schetelig, Christian Thiede, Rainer Schwerdtfeger, G. Ehninger, Andreas Neubauer, Axel R. Zander, N Kröger, Klaus Höffken, Michael G. Kiehl, Martin Bornhäuser, Herbert G. Sayer, J. Kienast
Publikováno v:
Journal of Clinical Oncology. 21:2747-2753
Purpose: To study whether hematopoietic stem-cell transplantation (HSCT) after reduced-intensity conditioning is effective and tolerable in patients with advanced chronic lymphocytic leukemia (CLL). Patients and Methods: Thirty patients with advanced